Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 894K | 895K | 530K | 577K |
| Gross Profit | 575K | 510K | 182K | 178K |
| Operating Income | -19M | -27M | -26M | -10M |
| EBITDA | -20M | -25M | -26M | -11M |
| Net Income | -22M | -26M | -26M | -12M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$1.76
-7.37% today
1Y Change
+39.57%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mainz Biomed N.V. (QUCY) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.76 and up 39.6% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +65.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.2%, EPS +65.5%, free cash flow +27.2% with operating margin -2091.2% and ROIC -192.9%. Valuation sits in the middle of the pack at price/sales 5.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QUCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QUCY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QUCY Max Drawdown
-84.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QUCY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$577.3K
+9.0% YoY
FY Net Income
-$11.7M
+55.7% YoY
Free Cash Flow
-$3.2M
+79.0% YoY
Revenue Growth
-0.2%
EPS Growth
+65.5%
Gross Margin
64.3%
Net Margin
-2421.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 894K | 895K | 530K | 577K |
| Gross Profit | 575K | 510K | 182K | 178K |
| Operating Income | -19M | -27M | -26M | -10M |
| EBITDA | -20M | -25M | -26M | -11M |
| Net Income | -22M | -26M | -26M | -12M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 6M | 7M | 17M | 9M |
| Total Assets | 13M | 15M | 20M | 10M |
| Total Liabilities | 7M | 12M | 6M | 4M |
| Shareholder Equity | 6M | 3M | 14M | 6M |
| Total Debt | 3M | 7M | 3M | 3M |
| Net Debt | -3M | 350K | -14M | -6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+78.2% YoY
Capital Expenditures
17K
+97.5% YoY
Free Cash Flow
3M
+79.0% YoY
Key ratios
Gross Margin
64.3%
Operating Margin
-2091.2%
Net Margin
-2421.8%
ROE
-465.8%
Debt / Equity
0.54x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.